FYI FDA changes labeling Stratterra

Posted by River1924 on February 6, 2007, at 23:50:32

* Atomoxetine therapy should not be used in patients with structural cardiac abnormalities or other serious heart conditions because of the potential increased vulnerability to its noradrenergic effects, leading to sudden death and other serious cardiovascular events. Use of atomoxetine at normal doses has also been linked to treatment-emergent psychotic/manic symptoms in pediatric patients with no prior history of such events.

Thread

FYI FDA changes labeling Stratterra River1924 2/6/07
Re: FYI FDA changes labeling Stratterra » River1924 Phillipa 2/7/07
Re: FYI FDA changes labeling Stratterra » River1924 River1924 2/7/07

Post a new follow-up

Notify the administrators

Start a new thread

poster:River1924 thread:730662
URL: http://www.dr-bob.org/babble/20070201/msgs/730662.html

	for
in